These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 33825723

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cilostazol for intermittent claudication.
    Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G.
    Cochrane Database Syst Rev; 2014 Oct 31; 2014(10):CD003748. PubMed ID: 25358850
    [Abstract] [Full Text] [Related]

  • 3. [Clinical study of efficacy and safety of Aducil in patients with chronic lower limb ischaemia].
    Suchkov IA, Kalinin RE, Gadzhimuradov RU, Lar'kov RN, Uchkin IG, Chupin AV, Parshin PI, Kamaev AA, Porsheneva EV.
    Angiol Sosud Khir; 2019 Oct 31; 25(3):29-37. PubMed ID: 31503245
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
    Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE, Bortey EB, Forbes WP.
    Arch Intern Med; 1999 Sep 27; 159(17):2041-50. PubMed ID: 10510990
    [Abstract] [Full Text] [Related]

  • 6. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
    Guest JF, Davie AM, Clegg JP.
    Curr Med Res Opin; 2005 Jun 27; 21(6):817-26. PubMed ID: 15969881
    [Abstract] [Full Text] [Related]

  • 7. Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis.
    Liang X, Wang Y, Zhao C, Cao Y.
    PLoS One; 2022 Jun 27; 17(11):e0275392. PubMed ID: 36318524
    [Abstract] [Full Text] [Related]

  • 8. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
    Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, Forbes WP.
    J Vasc Surg; 1998 Feb 27; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
    Regensteiner JG, Ware JE, McCarthy WJ, Zhang P, Forbes WP, Heckman J, Hiatt WR.
    J Am Geriatr Soc; 2002 Dec 27; 50(12):1939-46. PubMed ID: 12473004
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
    Lee TM, Su SF, Tsai CH, Lee YT, Wang SS.
    Clin Sci (Lond); 2001 Sep 27; 101(3):305-11. PubMed ID: 11524048
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
    Samra SS, Bajaj P, Vijayaraghavan KS, Potdar NP, Vyas D, Devani RG, Ballary C, Desai A.
    J Indian Med Assoc; 2003 Sep 27; 101(9):561-2, 564. PubMed ID: 15168999
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cilostazol: a novel treatment option in intermittent claudication.
    Cariski AT.
    Int J Clin Pract Suppl; 2001 Apr 27; (119):11-8. PubMed ID: 11355274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.